Developing national guidance on genetic testing for breast cancer predisposition: The role of economic evidence?

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 6, 2012, Pages 580-591

  Sullivan, William ^a   Evans, D Gareth ^b   Newman, William G ^b   Ramsden, Simon C ^b   Scheffer, Hans ^c   Payne, Katherine ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DNA SEQUENCE; EVIDENCE BASED PRACTICE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; PATIENT GUIDANCE; RESOURCE MANAGEMENT; SYSTEMATIC REVIEW (TOPIC); TELECONSULTATION; UNITED KINGDOM;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; ENGLAND; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEALTH POLICY; HUMANS; INTERVIEWS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; WALES;

EID: 84862980777     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0236     Document Type: Article

References (41)

1. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. [Summary for patients in Ann Intern Med 2006, 144:I40; PMID: 16549849]. Ann Intern Med 144:397-406. (Pubitemid 46768161)
2. Balmana J, Sanz J, Bonfill X, Casado A, Rue M, Gich I, Diez O, Sabate JM, Baiget M, Alonso MC (2004) Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer 112: 647-652. (Pubitemid 39425945)
3. Basu A, Meltzer D (2005) Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 24:751-773. (Pubitemid 40800157)
4. Cancer Research Uk (2011) Breast Cancer: UK Incidence Statistics. London. Available at http://info.cancerresearchuk.org/ cancerstats/types/breast/ incidence/#prev, (accessed October 15, 2011). (Online).
5. Caro JJ, Nord E, Siebert U, Mcguire A, Mcgregor M, Henry D, De Pouvourville G, Atella V, Kolominsky-Rabas P (2010) The efficiency frontier approach to economic evaluation of healthcare interventions. Health Econ 19:1117-1127.
6. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232-242. (Pubitemid 21891587)
7. Clinical Molecular Genetics Society (2011) Clinical Molecular Genetics Society Audit 2009-2010. Clinical Molecular Genetics Society, London.
8. Craig D, Rice S, Aguiar-Ibáñez R, Glanville J, Kleijnen J, Drummond M (2007) Chapter III: guidance for writing NHS EED abstracts. In: Craig D, Rice S (eds) NHS Economic Evaluation Database Handbook, 3rd edition. Centre for Reviews and Dissemination, University of York, York, United Kingdom.
9. CRD (2011) Centre for Reviews and Dissemination: Identifying Studies for Inclusion in NHS EED: Search Filter Resource. London. Available at www.york.ac.uk/inst/crd/intertasc/ nhs-eed-strategies.html, (accessed July 25, 2011). (Online).
10. Drummond MF, Sculpher M, Torrance GW, O'brien B, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford.
11. Esteban-Cardenosa E, Duran M, Infante M, Velasco E, Miner C (2004) High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis. Clin Chem 50:313-320. (Pubitemid 38156371)
12. Evans DG, Eccles D, Rahman N, Young KC, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474-480. (Pubitemid 38788046)
13. Evans DG, Howell A (2007) Breast cancer risk-assessment models. Breast Cancer Res 9:213.
14. Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI (2000) Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/ 2-positive women: a decision analysis. Cancer J Sci Am 6: 13-20. (Pubitemid 30078500)
15. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979-985. (Pubitemid 28108730)
16. Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI (1999) Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 17:494-500. (Pubitemid 29075233)
17. Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach MO; UK Magnetic Resonance Imaging in Breast Screening (MARIBS) Study Group (2006) Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 95:801-810. (Pubitemid 44498093)
18. Grosse SD, Wordsworth S, Payne K (2008) Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 10:648-654.
19. Heimdal K, Maehle L, Moller P (1999) Costs and benefits of diagnosing familial breast cancer. Dis Markers 15:167-173. (Pubitemid 29520761)
20. Holland ML, Huston A, Noyes K (2009) Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health 12:207-216.
21. House of Lords Science and Technology Committee (2009) House of Lords Science and Technology Committee, 2nd Report of Session 2008-2009: "Genomic Medicine". London: House of Lords.
22. Hutchison CA (2007) DNA sequencing: bench to bedside and beyond. Nucleic Acids Res 35:6227-6237.
23. Lewingroup (2009) The Value of Diagnostic Screening and Laboratory Tests for Prevention and Health Care Improvement. The Lewin Group, Falls Church, Virginia.
24. Mcintosh A, Shaw C, Evans DG, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, Mckay J, Sheppard C, Sibbering M, Watson W, Wailoo A (2004) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, London.
25. MRC (2009) Medical Research Council. News & Publications. Further MRC Investment in High-Throughput Sequencing. Available at www.mrc.ac.uk/ Newspublications/News/ MRC006188, (accessed May 3, 2010). (Online).
26. National Institute for Health and Clinical Excellence (2008) Guide to the Methods of Technology Appraisal. National Health Service National Institute for Health and Clinical Excellence, London.
27. Newman B, Austin MA, Lee M, King MC (1988) Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 85:3044-3048.
28. Norman RPA, Evans DG, Easton DF, Young KC (2007) The costutility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ 8:137-144. (Pubitemid 46742897)
29. Norum J, Hagen AI, Maehle L, Apold J, Burn J, Moller P (2008) Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer 44:963-971.
30. Payne K (2009) Fish and chips all round? Regulation of DNA-based genetic diagnostics. Health Econ 18:1233-1236.
31. Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K (2005) Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test 9:48-53. (Pubitemid 40586430)
32. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S (2006) Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24:355-371.
33. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM (2006) Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295:2374-2384. (Pubitemid 43788105)
34. Reis MM, Tavakoli M, Dewar J, Goudie D, Cook A, Mcleish L, Young D, Kenyon J, Steel M (2009) Evaluation of a surveillance programme for women with a family history of breast cancer. J Med Genet 46:319-323.
35. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74:5463-5467.
36. Sevilla C, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-De Paillerets B, Sobol H, Moatti J-P (2003) Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. Int J Technol Assess Health Care 19:287-300. (Pubitemid 36818673)
37. Sevilla C, Moatti, J-P, Julian-Reynier C, Eisinger F, Stoppa- Lyonnet D, Bressac-De Paillerets B, Sobol H (2002) Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 10:599-606. (Pubitemid 35277292)
38. Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17-22.
39. Sullivan W, Payne K (2011) The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose. Pharmacoeconomics 29:455-459.
40. Tengs TO, Berry DA (2000) The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Dis Manage Clin Outcomes 1:15-24. (Pubitemid 30225762)
41. Wilson BJ, Torrance N, Mollison J, Wordsworth S, Gray JR, Haites NE, Grant A, Campbell MK, Miedyzbrodzka Z, Clarke A, Watson MS, Douglas A (2005) Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions. Health Technol Assess 9:iii-iv, 1-126.